Abstract: The present invention provides a method for efficiently producing highly pure ??T cells introduced with foreign genes by culturing in the presence of IL-7 and IL-15 after stimulating the ??T cells with a bisphosphonic acid ester derivative. When a T cell receptor (TCR) or a chimeric antigen receptor (CAR) is introduced as a foreign gene, ??T cells in which TCR and CAR are functionally expressed can be obtained.

Abstract: A nitride semiconductor substrate (11, 21) includes: a substrate (2); and an AlN-containing film (100, 200) provided above the substrate (2). A thickness of the AlN-containing film (100, 200) is at most 10000 nm, and a threading dislocation density of the AlN-containing film (100, 200) is at most 2×108 cm?2.

Abstract: An antigen-loaded nanogel is formed by loading or encapsulating one or more long peptide antigens or one or more protein antigens in a hydrophobized polysaccharide. The long peptide antigen(s) or protein antigen(s) contains (or each contain) one or more CD8+ cytotoxic T cell recognition epitopes and/or one or more CD4+ helper T cell recognition epitopes, which is/are derived from the antigen. The antigen-loaded nanogel is administered at least one day prior to administration of antigen-specific T cells to improve the efficacy of a T cell infusion therapy against an immune checkpoint inhibitor-resistant tumor. The hydrophobized polysaccharide may be pullulan having cholesteryl groups bound thereto. An immune-enhancing agent also may be administered in or with the antigen-loaded nanogel.

Abstract: The compound that is contained in a young watermelon fruit and is represented by the formula (1) or formula (2) has an antioxidative effect and further has a skin anti-aging effect. Since these compounds are extracts from plants that are naturally edible, they are very safe for human bodies. Therefore, an antioxidative pharmaceutical composition, an antioxidative processed food composition, and an anti-skin aging composition, which contain these compounds as active ingredients, have high utility value as highly safe compositions.

Abstract: An object of the present invention is to provide a technique for preventing or treating HTLV-1-associated diseases, such as ATL, a material for use in the technique, a method for screening the material, and the like. The present invention provides a TCR screening method comprising sorting HTLV-1-derived antigen-recognizing cells from cells derived from an HTVL-1 patient and subjecting the HTLV-1-derived antigen-recognizing cells to TCR repertoire analysis, ranking the TCR types in descending order of the number of cells of each TCR type, and selecting a highly ranked TCR. The present invention provides a prophylactic or therapeutic agent for an HTLV-1-associated disease, the agent comprising a TCR comprising specific CDRs that can be obtained by the TCR screening method and cells expressing the TCR.

Abstract: A nitride semiconductor substrate (11, 21) includes: a substrate (2); and an AlN-containing film (100, 200) provided above the substrate (2). A thickness of the AlN-containing film (100, 200) is at most 10000 nm, and a threading dislocation density of the AlN-containing film (100, 200) is at most 2×108 cm?2.

Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Abstract: Phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. However, there is a problem that an amount of phytol to be taken for exhibiting cancer cell growth inhibition is large. A cancer cell growth inhibiting composition comprising at least one of compounds having a structure represented by Formula (1), Formula (2), Formula (6), Formula (7) or Formula (8), or a pharmaceutically acceptable salt thereof as main components has a higher cancer cell growth inhibiting effect than phytol.

Abstract: A method of treating a patient in need thereof includes administering a therapeutically effective amount of 4-deoxy-L-erythro-5-hexoseulose uronic acid (DEH) to serve or function as a nerve growth factor (NGF) activity promoter, preferably to treat and/or prevent a neurodegenerative disease, such as PolyQ disease, Parkinson's disease, Parkinson's syndrome, spinocerebellar degeneration, spastic paraplegia, amyotrophic lateral sclerosis, Alzheimer's disease, dementia with Lewy bodies or corticobasal degeneration.

Abstract: A resin composition including a lignin skeleton capable of producing a heat-resistant molded article and being decomposed under relatively mild conditions. The resin composition contains a lignin skeleton including, as a base component, a phenolated lignin or a derivative thereof that contains a reactive monomer group, the phenolated lignin containing a phenol-containing monomer represented by the following general formula (I): wherein R1 to R5 are each independently a monovalent group selected from H, OH, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, and a C6to C10 aryl group, or adjacent substituents among R1 to R5 form a substituted or unsubstituted aromatic ring together, at least one of R1 and R2 is a hydroxyl group, and R6 is OCH3 or H; a molded article thereof, as well as a recycling method for a molded article formed in a mold formed of the resin composition.

Abstract: A nucleic acid molecule having a nucleotide sequence encoding a chimeric antigen receptor, where the nucleic acid molecule includes a segment encoding an extracellular domain, a segment encoding a transmembrane domain, and a segment encoding an intracellular domain. The segment encoding the extracellular domain includes a nucleotide sequence encoding an antigen binding region including a light chain variable region and a heavy chain variable region, and at least three codons in a nucleotide sequence encoding framework region 3 of the light chain variable region as defined by the Chothia method are codons encoding acidic amino acid residues.

Abstract: A III nitride light-emitting device comprises: a template member having a template layer that includes compressive strain and covers the principal surface including AlXGa1-XN that has a full width at half maximum of a (10-12)-face X-ray rocking curve with 1000 arcsec or lower, where X is greater than zero and 1 or less; an active layer including a compressively strained AlGaN and generating light having a peak wavelength in deep ultraviolet wavelengths of 285 nm or below; and an n-type III nitride semiconductor region disposed on the template member. The n-type III nitride semiconductor region has an n-type first and second III nitride semiconductor layers on the template member. The n-type first III nitride semiconductor layer has a lattice relaxation rate of 2% or less relative to that of the template layer, and the n-type second III nitride semiconductor layer has a surface roughness of 0.4 nm or less.

Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Abstract: Provided is a vital stain inspection method for distinguishing between cancer cells and normal cells within a lumen, or on the serous membrane side of an organ, by means of laser irradiation after organ tissue has been stained by curcumin, Red #3 or Red #106, which are edible color dyes.

Abstract: A cancer test device (1) is provided with: an application unit (40) for applying a staining agent (45), which can selectively stain a product of a cancer-relating gene in a living cell a chromatic color, onto a group of living cells; an imaging unit (10) for imaging the group of living cells having the staining agent (45) applied thereto; and a determination unit (52) for determining the level of malignancy of cancerization of the group of living cells on the basis of the state of the stained expression pattern of the cancer-relating gene in the group of living cells in an image obtained by the aforementioned imaging.

Abstract: A method of treating a patient in need thereof includes administering a therapeutically effective amount of 4-deoxy-L-erythro-5-hexoseulose uronic acid (DEH) to serve or function as a nerve growth factor (NGF) activity promoter, preferably to treat and/or prevent a neurodegenerative disease, such as PolyQ disease, Parkinson's disease, Parkinson's syndrome, spinocerebellar degeneration, spastic paraplegia, amyotrophic lateral sclerosis, Alzheimer's disease, dementia with Lewy bodies or corticobasal degeneration.

Abstract: Staphylococcus nepalensis releases corisin, a peptide conserved in diverse Staphylococci, that induces apoptosis of lung epithelial cells. Therefore, methods and apparatus for detecting the presence of corisin in a biological sample of a patient are disclosed, as well as pharmaceutical compositions, such as antibodies, and methods for treating patents having or suspected of having fibrosis.

Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.